Rex Bionics
Auckland
About Rex Bionics
Rex Bionics Plc is engaged in the research and development, manufacture, and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $27.8M
- Funding stage: M&A
- Last round: Grant (Jul 2024)
- Ticker: lse:RXB
- Website: rexbionics.com
- Phone: +64 9 440 9741
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical, Robotics
Social Profiles
Canonical: https://fsome.com/organization/rex-bionics-171166 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.